ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2020.69.04ymj-2919Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHВзаимосвязь носительства мутации JAK2V617F и частоты тромботических осложнений среди пациентов с классическими Ph-негативными хроническими миелопролиферативными заболеваниямиAssociation between JAK2V617F mutation and thrombotic complication in patients with classical Ph-negative chronic myeloproliferative diseasesАлександроваТ. Н.AleksandrovaT. N.

АЛЕКСАНДРОВА Туйара Никоновна – м.н.с., врач-гематолог РБ№1-НЦМ

ALEKSANDROVA Tuiara Nikonovna – junior researcher of the laboratory of heritable pathology Yakut Science Centre of complex medical problems, hematologist of National Centre of Medicine

alexandrova_tuyara@mail.ruМулинаИ. И.MulinaI. I.

МУЛИНА Инна Ивановна – гл. внештат. гематолог МЗ РС(Я), зав. отделением

MULINA Inna Ivanovna – Head of the Department of hematology 

КуртановХ. А.KurtanovK. A.

КУРТАНОВ Харитон Алексеевич – к.м.н., гл. н.с.-руковод. отдела

KURTANOV Khariton Alekseevich – Candidate of medical sciences, chief researcher – Head of department of molecular genetics

hariton_kurtanov@mail.ruСоловьеваИ. Е.SolovievaI. E.

СОЛОВЬЕВА Ирина Еремеевна – врач-гематолог

SOLOVIEVA Irina Eremeevna – hematologist

ТереховаЛ. Д.TerekhovaL. D.

ТЕРЕХОВА Лена Дмитриевна – врач-гематолог

ПавловаН. И.PavlovaN. I.

ПАВЛОВА Надежда Ивановна – к.б.н., в.н.с.

PAVLOVA Nadezhda Ivanovna – Candidate of Biological Sciences, leading researcher, Head of hereditary pathology laboratory

ЯдрихинскаяВ. Н.YadrikinskayaV. N.

ЯДРИХИНСКАЯ Вера Николаевна – к.м.н., доцент МИ 

YADRIKHINSKAYA Vera Nikolaevna – candidate of medical sciences, associate professor of department «Hospital therapy, professional diseases, clinical pharmacology» Medical Institute

СоловьеваН. А.SolovievaN. A.

СОЛОВЬЕВА Наталья Алексеевна – к.м.н., с.н.с.

SOLOVIEVA Natalya Alekseevna – researcher of the Laboratory of Population Genetics

ДьяконоваА. Т.DyakonovaA. T.

ДЬЯКОНОВА Александра Тимофеевна – м.н.с.

DYAKONOVA Aleksandra Timofeevna – junior researcher of the laboratory of heritable pathology

ЯНЦ КМПРоссияYakut Science Centre of complex medical problems; National Centre of MedicineRussian FederationРБ№1-Национальный центр медицины, г. ЯкутскРоссияNational centre of MedicineRussian FederationЯНЦ КМПРоссияYakut Science Centre of complex medical problemsRussian FederationСВФУ им. М.К. АммосоваРоссияNorth-Eastern Federal UniversityRussian Federation202017112025012123Copyright © Александрова Т.Н., Мулина И.И., Куртанов Х.А., Соловьева И.Е., Терехова Л.Д., Павлова Н.И., Ядрихинская В.Н., Соловьева Н.А., Дьяконова А.Т., 20252025Александрова Т.Н., Мулина И.И., Куртанов Х.А., Соловьева И.Е., Терехова Л.Д., Павлова Н.И., Ядрихинская В.Н., Соловьева Н.А., Дьяконова А.Т.Aleksandrova T.N., Mulina I.I., Kurtanov K.A., Solovieva I.E., Terekhova L.D., Pavlova N.I., Yadrikinskaya V.N., Solovieva N.A., Dyakonova A.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/2919

Исследование проведено с целью оценки влияния клинико-лабораторных показателей и мутации JAK2V617F на частоту развития тромботических осложнений среди пациентов с классическими Ph-негативными хроническими миелопролиферативными заболеваниями. Мутация JAK2V617F выявлена у больных истинной полицитемией, эссенциальной тромбоцитемией и первичным миелофиброзом. Тромботические осложнения достоверно чаще наблюдались у носителей мутации JAK2V617F и больных, имеющих сердечно-сосудистые факторы риска.

The study was conducted with aim to assess the effect of clinical and laboratory parameters and JAK2V617F mutation on the incidence of thrombotic complications in patients with classical Ph-negative chronic myeloproliferative diseases. JAK2V617F mutation was detected in patients with polycythemia vera, essential thrombocythemia and patients with primary myelofibrosis. Thrombotic complications were significantly more often observed in carriers of the JAK2V617F mutation and in patients with cardiovascular risk factors.

хронические миелопролиферативные заболеванияJAK2V617Fтромбозыchronic myeloproliferative diseasesJAK2V617FthrombosisReferencesКлинические особенности эссенциальной тромбоцитемии и первичного миелофиброза в зависимости от молекулярных характеристик заболевания / А.Л. Меликян, И.Н. Суборцева, А.Б. Судариков [и др.] // Терапевтич. архив. – 2017. – Т.89, №7. – С.4-9. DOI: 10.17116/terarkh20178974-9Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease / A.L. Melikyan, IN Subortseva, AB Sudarikov [et al] // Therapeutic archive. – 2017. – T.89, №7. – P.4-9. DOI: 10.17116/terarkh20178974-9Меликян А.Л. Миелопролиферативные новообразования: новые данные / А.Л. Меликян, И.Н. Суборцева // Клинич. онкогематология. – 2016. –Т.9, №2. – С.218-228.Melikyan A.L. Myeloproliferative neoplasia: new data / A.L. Melikyan, I.N. Subortseva // Clinical oncohematology. – 2016.– Vol.9, №2. – P. 218-228.Что нам известно об истинной полицитемии (обзор литературы и собственные данные) / К.М. Абдулкадыров, В.А. Шуваев, И.С. Мартынкевич // Онкогематология. – 2015. – Т.10, № 3. – С.28-42. DOI: 10.17650/1818-8346-2015-10-3-28-42.All we know about polycythemia vera: literature review and own experience / K.M. Abdulkadyrov, V.A. Shuvaev, I.S. Martynkevich // Oncohematology. – 2015. – Vol.10, №3. – P.28-42. DOI: 10.17650/1818-8346-2015-10-3-28-42.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [published correction appears in Lancet / EJ Baxter, LM Scott, PJ Campbell // Lancet. – 2005. – Vol.9464, №365. – Р.1054–1061. DOI:10.1016/S0140-6736(05)71142-9Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [published correction appears in Lancet / EJ Baxter, LM Scott, PJ Campbell // Lancet. – 2005. – Vol.9464, №365. – Р.1054–1061. DOI:10.1016/S0140-6736(05)71142-9Arachchillage DR. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms / DR Arachchillage, M Laffan // Semin Thromb Hemost. 2019. Vol. 45, №6. – Р.604–611. DOI:10.1055/s-0039-1693477Arachchillage DR. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms / DR Arachchillage, M Laffan // Semin Thromb Hemost. 2019. Vol. 45, №6. – Р.604–611. DOI:10.1055/s-0039-1693477Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms / B Duangnapasatit, E Rattarittamrong, T Rattanathammethee // Asian Pac J Cancer Prev. – 2015. – Vol.16, №12. P. 5013-5018. DOI: 10.7314/apjcp.2015.16.12.5013Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms / B Duangnapasatit, E Rattarittamrong, T Rattanathammethee // Asian Pac J Cancer Prev. – 2015. – Vol.16, №12. P. 5013-5018. DOI: 10.7314/apjcp.2015.16.12.5013Martin K. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis / K Martin // Curr Hematol Malig Rep. – 2017. – Vol. 12, №5. – Р.389-396. DOI: 10.1007/s11899-017-0400-3.Martin K. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis / K Martin // Curr Hematol Malig Rep. – 2017. – Vol. 12, №5. – Р.389-396. DOI: 10.1007/s11899-017-0400-3.Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial / M Griesshammer, G Saydam, F Palandri [et al] // Annals of Hematology. – 2018. Vol.97. – P.1591–1600. DOI: 10.1007/s00277-018-3365-yRuxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial / M Griesshammer, G Saydam, F Palandri [et al] // Annals of Hematology. – 2018. Vol.97. – P.1591–1600. DOI: 10.1007/s00277-018-3365-yThrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms / S Ball, KZ Thein, A Maiti [et al] // J Thromb Thrombolysis. – 2018. – T.45, №4. – Р.516–528. DOI:10.1007/s11239-018-1623-4Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms / S Ball, KZ Thein, A Maiti [et al] // J Thromb Thrombolysis. – 2018. – T.45, №4. – Р.516–528. DOI:10.1007/s11239-018-1623-4Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management / A. Casini, P. Fontana, TP. Lecompte // J Thromb Haemost. – 2013. – Vol.11, №7. – P.1215-1227. DOI: 10.1111/jth.12265Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management / A. Casini, P. Fontana, TP. Lecompte // J Thromb Haemost. – 2013. – Vol.11, №7. – P.1215-1227. DOI: 10.1111/jth.12265

The authors declare that there are no conflicts of interest present.